Drugs / Yttrium Y 90 Basiliximab
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05139004 | Jul 2022 → Jun 2027 expected | acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02342782 | Jun → Sep 2020 | mature T-cell and NK-cell non-Hodgkin lymphoma, primary cutaneous T-cell non-Hodgkin lymphoma | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01476839 | Nov 2012 → Jul 2021 | Hodgkins lymphoma | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04871607 | Nov 2021 → Oct 2029 expected | Hodgkins lymphoma | City of Hope Medical Center | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | yttrium Y 90 basiliximab | “Patients receive basiliximab IV and yttrium Y 90 basiliximab IV on day -14.” NCT01476839 ↗ |
| Action | Deplete | “Basiliximab attaches to CD25 positive cancer cells in a targeted way and delivers 90Y-DOTA to kill them” NCT05139004 ↗ |
| Modality | Monoclonal antibody | “Radioactive substances linked to monoclonal antibodies, such as yttrium Y 90 basiliximab” NCT02342782 ↗ |
| Route | Intravenous | “Given IV” NCT02342782 ↗ |